الفهرس 
Aspirin and cardiovascular diseasesOnly 14 pages are availabe for public view
Abstract
Background: By 2030, almost 23.6 million people will die from CVDs, mainly from heart disease and stroke. Aspirin resistance can be diagnosed clinically by the occurrence of an atherothrombotic ischemic event in a patient taking a therapeutic dose of aspirin
Objective: to assess the Relationship between obesity and aspirin resistance both clinically and biochemical among elderly patients
Methods: case control study was conducted on 60 elderly patients (30 obese, 30 non-obese) from the geriatric medicine department and out-patient clinic, who underwent comprehensive geriatric assessment, serum lipid levels measurement, urinary 11-dehydro-thromboxaneB2 measurment.
Results: Among the studied population 30 patients (50%) have clinical aspirin resistance.
Clinical aspirin resistance was significantly related to total cholesterol and LDL level. Clinically resistant group had higher total cholesterol (245.6 vs 176.3, P<0.001) and higher LDL (136.5 vs. 111.3, P=0.014) than non resistant group.
Cerebro-vascular disease was the most prevalent co-morbidities among clinically resistant group than clinically non-resistant group (18 vs. 8, P= 0.009)
No significant difference was found as regard age, sex, smoking habits and drug use between two groups.
Conclusion:
Elderly patients with higher levels of Total Cholesterol and LDL have clinical aspirin resistance compared to those with lower levels of Total Cholesterol and LDL.
Cerebro-vascular disease was the most prevalent co-morbidities among those elderly with clinically resistant group than clinically non-resistant group.